Zevra Therapeutics, Inc. ZVRA

11.04 (0.22) (1.95%) as of 25 Sep
Market cap
$668.7M
P/E
11.6×

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Revenue
106.47 23.61 27.46 10.16 28.65 13.29 12.84 — — —
Revenue Growth
350.91% (14.02%) 170.26% (64.53%) 115.61% 3.50% (3.38%) — — —
Cost of Revenue
16.48 7.42 2.17 0.22 2.06 1.31 2.95 0.32 0.34 0.18
Gross Profit
89.99 16.20 25.29 9.94 26.59 11.98 9.89 (0.32) (0.34) (0.17)
R&D Expenses
12.74 42.10 39.81 19.80 10.16 8.84 19.42 41.76 20.59 20.47
SG&A Expenses
77.62 54.87 34.31 15.04 8.70 8.75 10.82 14.14 12.77 17.01
Operating Income
(62.94) (87.00) (49.60) (42.56) 7.73 (5.61) (20.34) (55.90) (33.37) (37.48)
Non-operating Income/Expense
149.62 (3.14) 3.56 15.76 (16.25) (7.18) (4.21) (0.69) (10.06) 20.95
Non-operating Interest Expenses
7.98 7.35 1.50 0.34 0.38 7.09 6.51 7.09 7.34 7.13
EBT
86.68 (90.14) (46.05) (26.80) (8.52) (12.79) (24.54) (56.59) (43.43) (16.53)
Income Tax Provision
3.45 15.37 — (0.03) 0.03 (0.03) (0.02) (0.13) (0.04) (0.01)
Income after Tax
83.23 (105.51) (46.05) (26.77) (8.55) (12.76) (24.52) (56.47) (43.39) (16.52)
Dividends (Preferred)
5.64 — — 0.00 54.34 — — — — —
Net Income Common
77.59 (105.51) (46.05) (26.77) (62.90) (12.76) (24.52) (56.47) (43.39) (16.52)
EPS (Basic)
1.40 (2.28) (1.30) (0.78) (2.11) (3.21) (13.28) (50.40) (47.36) (18.08)
EPS (Diluted)
1.35 (2.28) (1.30) (0.78) (2.11) (3.21) (13.28) (50.40) (47.36) (18.08)
Shares (Basic, Weighted)
55.31 46.25 35.45 34.49 29.77 3.98 1.85 1.12 0.92 0.91
Shares (Diluted, Weighted)
57.26 46.25 35.45 34.49 29.77 3.98 1.85 1.12 0.92 0.91
Gross Margin
84.52% 68.59% 92.09% 97.82% 92.81% 90.18% 77.06% 0.00% 0.00% 0.00%
EBIT Margin
(59.12%) (368.47%) (180.63%) (418.91%) 26.98% (42.21%) (158.40%) 0.00% 0.00% 0.00%
EBT margin
81.41% (381.76%) (167.69%) (263.80%) (29.74%) (96.28%) (191.17%) 0.00% 0.00% 0.00%
Net Profit Margin
72.87% (446.85%) (167.69%) (263.48%) (219.54%) (96.03%) (191.00%) 0.00% 0.00% 0.00%
Free Cash Flow Margin
(1.86%) (295.04%) (123.20%) (185.12%) 36.08% (14.84%) (185.08%) 0.00% 0.00% 0.00%
EBITDA
(3.31) (81.50) (48.60) (41.62) 8.14 (3.03) (18.38) (53.96) (31.47) (35.69)
EBIT
(62.94) (87.00) (49.60) (42.56) 7.73 (5.61) (20.34) (55.90) (33.37) (37.48)
Income from Continuous Operations
83.23 (105.51) (46.05) (26.77) (8.55) (12.76) (24.52) (56.47) (43.39) (16.52)
Consolidated Net Income/Loss
83.23 (105.51) (46.05) (26.77) (8.55) (12.76) (24.52) (56.47) (43.39) (16.52)
EPS (Basic, from Continuous Ops)
1.50 (2.28) (1.30) (0.78) (0.29) (3.21) (13.23) (50.39) (47.37) (18.10)
EPS (Basic, Consolidated)
1.50 (2.28) (1.30) (0.78) (0.29) (3.21) (13.23) (50.39) (47.37) (18.10)
EPS (Diluted, from Cont. Ops)
1.45 (2.28) (1.30) (0.78) (0.29) (3.21) (13.23) (50.39) (47.37) (18.10)
Shares (Diluted, Average)
57.26 46.25 35.45 34.49 29.77 3.98 1.85 1.12 0.92 0.91
EPS (Diluted, Consolidated)
1.45 (2.28) (1.30) (0.78) (0.29) (3.21) (13.23) (50.39) (47.37) (18.10)
EBITDA Margin
(3.11%) (345.18%) (176.97%) (409.62%) 28.40% (22.81%) (143.13%) 0.00% 0.00% 0.00%
Operating Cash Flow Margin
(1.50%) (295.04%) (122.12%) (184.20%) 36.44% (14.59%) (184.88%) 0.00% 0.00% 0.00%

Fold the line items

In millions of $ except per-share values · columns are period end dates